drugset
Drugs / Icodec
last change Nov 2024 re-read 3 minutes ago

Icodec

Developed for
type 2 diabetes mellitus
Investigated by
Novo Nordisk A/S

Trials 1

today NCT03789578 · Ph 1
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03789578 Jan → Oct 2019 type 2 diabetes mellitus Novo Nordisk A/S Completed No outcome recorded

Press releases naming this drug 6 releases

DateIssuerRelease
2024-07-10 Novo Nordisk A/S Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec novonordisk.com ↗
2024-03-21 Novo Nordisk A/S Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities novonordisk.com ↗
2022-10-03 Novo Nordisk A/S Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in ONWARDS 5 phase 3a trial novonordisk.com ↗
2022-07-29 Novo Nordisk A/S Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3 novonordisk.com ↗
2022-06-03 Novo Nordisk A/S Novo Nordisk achieves primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in ONWARDS 1 novonordisk.com ↗
2022-04-28 Novo Nordisk A/S Once-weekly insulin icodec demonstrates superior reduction in HbA1c vs insulin degludec in people with type 2 diabetes in ONWARDS 2 phase 3a trial novonordisk.com ↗

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Icodec “received single subcutaneous injections of IcoSema (175 U icodec, 0.5 mg semaglutide), icodec (175 U) or semaglutide (0.5 mg) with 6-9 weeks' washout.” PMID 39488821 ↗ Nov 2024